A5027353165- Coronary Interventions and Diagnostics
- Cardiac Valve Diseases and Treatments
- Cardiac Imaging and Diagnostics
- Infective Endocarditis Diagnosis and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Aortic Disease and Treatment Approaches
- Cerebrovascular and Carotid Artery Diseases
- Atrial Fibrillation Management and Outcomes
- Advanced MRI Techniques and Applications
- Cardiac pacing and defibrillation studies
- Cardiovascular Function and Risk Factors
- Peripheral Artery Disease Management
- Cardiovascular and Diving-Related Complications
- Cardiac Arrhythmias and Treatments
- Venous Thromboembolism Diagnosis and Management
- Cardiac Structural Anomalies and Repair
- Cardiac electrophysiology and arrhythmias
- Aortic aneurysm repair treatments
- Traumatic Brain Injury and Neurovascular Disturbances
- Cardiac, Anesthesia and Surgical Outcomes
- Acute Ischemic Stroke Management
- ECG Monitoring and Analysis
- Mechanical Circulatory Support Devices
- Cardiac and Coronary Surgery Techniques
ZF Friedrichshafen (Germany)
2020-2025
Universität Ulm
2012-2024
University Hospital Ulm
2009-2023
Klinikum Ludwigshafen
2023
Medizin Campus Bodensee
2021-2022
Charité - Universitätsmedizin Berlin
2021
Deutsches Herzzentrum der Charité
2021
University Medical Center
2018
University Hospital and Clinics
2018
Albert Einstein College of Medicine
2014-2016
The relative merits of ticagrelor as compared with prasugrel in patients acute coronary syndromes for whom invasive evaluation is planned are uncertain.In this multicenter, randomized, open-label trial, we randomly assigned who presented and was to receive either or prasugrel. primary end point the composite death, myocardial infarction, stroke at 1 year. A major secondary (the safety point) bleeding.A total 4018 underwent randomization. end-point event occurred 184 2012 (9.3%) group 137...
Aims Because of its high spatial resolution and tissue contrast, magnetic resonance imaging (MRI) was used to assess cardiac structure function in a large population patients with acute myocardial infarction (AMI).
Whether the direct factor Xa inhibitor rivaroxaban can prevent thromboembolic events after transcatheter aortic-valve replacement (TAVR) is unclear.
Background— Restenosis requiring reintervention limits the long-term success after coronary stent implantation. Thiazolidinediones, like pioglitazone or rosiglitazone, are oral antidiabetic drugs with additional antirestenotic properties. In a randomized, placebo-controlled, double-blind trial, we examined effect of 6-month therapy on neointima volume stenting in nondiabetic artery disease patients. Methods and Results— Fifty patients implantation were randomly assigned to (30 mg daily; pio)...
The role of cerebral embolic protection (CEP) in transcatheter aortic valve replacement (TAVR) remains controversial. Randomized trials have not been powered to demonstrate a reduction stroke rates. aim this patient level pooled analysis was validate the impact dual-filter CEP device (Claret Medical Inc., CA, USA) on peri-procedural large number TAVR patients.Patients from SENTINEL US IDE trial were combined with CLEAN-TAVI and SENTINEL-Ulm study (N = 1306). Propensity score matching...
Background: Patients at high-bleeding risk (HBR) undergoing percutaneous coronary intervention represent a challenging patient population. The use of drug-coated balloon (DCB) allows shorter duration dual antiplatelet therapy compared with drug-eluting stents (DES) and reduces thrombotic due to the absence permanent implant. present analysis aimed investigate if effect DCB versus DES differed between patients without HBR treated in small arteries. Methods: This prespecified subgroup...
Background— In patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty, abciximab reduces major adverse cardiac events (MACE). Clinical trials have studied intravenous administration only. Intracoronary bolus application of causes very high local drug concentrations and may be more effective. We whether intracoronary is associated a reduced MACE rate compared the standard application. Methods Results— stratified 403 consecutive angioplasty according to...
AimsClinical parameters are weak predictors of outcome in patients with idiopathic dilated cardiomyopathy (IDC). We assessed the prognostic value cardiac magnetic resonance (CMR) addition to conventional clinical and electrocardiographic characteristics.
<h3>Background</h3> Percutaneous coronary intervention with stent implantation is limited by the occurrence of re-stenosis and risk thromboses. <h3>Objective</h3> To define impact paclitaxel-coated balloon angioplasty plus endothelial progenitor cell capturing (EPC) in de novo artery disease. This combination may reduce neointimal proliferation within EPC address thrombosis facilitating rapid endothelialisation. <h3>Methods</h3> In this prospective single-blind multicentre randomised trial,...
RESPOND is a prospective, open-label, single-arm study evaluating the outcomes following transcatheter aortic valve implantation (TAVI) with repositionable and fully retrievable Lotus Valve used in routine clinical practice for treatment of patients stenosis.RESPOND enrolled 1014 at sites across Europe, New Zealand, Latin America; 996 received (mean age: 80.8 years; 50.8% female; Society Thoracic Surgeons score: 6.0 ± 6.9). Repositioning was attempted 29.2% patients, 99% success. The rate...
The efficacy and safety of a reduced dose prasugrel versus standard ticagrelor in elderly patients or those with low body weight presenting an acute coronary syndrome (ACS) are unknown.To investigate the effect age- weight-adapted ACS. (ClinicalTrials.gov: NCT01944800).Prespecified analysis multicenter, randomized ISAR-REACT 5 trial.23 centers Germany Italy.3997 ACS planned for invasive management.Participants were randomly assigned to receive (reduced low-weight group neither nor group).The...
Paclitaxel-coated balloons (PCBs) are a preferred treatment option for coronary in-stent restenosis. To date, data from randomized trials of alternative drug coatings lacking. The aim the Malaysian and German-Swiss was to investigate novel sirolimus-coated balloon (SCB) compared with PCB in restenosis.One hundred one patients drug-eluting stent restenosis were enrolled 2 identical comparing SCB (SeQuent SCB, 4 μg/mm²) clinically proven Please, 3 μg/mm²). Primary end point angiographic late...